Hennion & Walsh Asset Management, Inc. Neurocrine Biosciences Inc Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.15 Billion
- Q1 2025
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 6,307 shares of NBIX stock, worth $810,008. This represents 0.03% of its overall portfolio holdings.
Number of Shares
6,307
Previous 5,167
22.06%
Holding current value
$810,008
Previous $705,000
1.13%
% of portfolio
0.03%
Previous 0.03%
Shares
12 transactions
Others Institutions Holding NBIX
# of Institutions
651Shares Held
96.1MCall Options Held
800KPut Options Held
565K-
Black Rock Inc. New York, NY14.2MShares$1.82 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.94MShares$1.28 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.53MShares$711 Million0.37% of portfolio
-
State Street Corp Boston, MA4.86MShares$624 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.67MShares$343 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $12.3B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...